| Overall (n = 135) | HAD group (n = 47) | Non-HAD group (n = 88) | p-value |
---|---|---|---|---|
Gender, male, n (%) | 73 (54.1) | 25 (53.2) | 48 (54.6) | 1.000 |
Age, year | 57.0 (52.0–62.0) | 57.0 (51.0–65.0) | 57.0 (52.0–62.0) | 0.701 |
BMI, kg/m2 | 19.6 (17.0–22.3) | 20.0 (17.0–22.1) | 19.5 (16.9–22.5) | 0.908 |
GNRI, points | 81.6 (73.7–90.9) | 81.6 (73.7–90.3) | 81.8 (72.8–91.1) | 0.702 |
 < 92 | 105 (77.8) | 38 (80.9) | 67 (76.1) | 0.665 |
 ≥ 92 | 30 (22.2) | 9 (19.2) | 21 (23.9) |  |
Type of disease, n (%) | ||||
 Primary biliary cirrhosis | 11 (8.1) | 6 (12.8) | 5 (5.7) | 0.557 |
 Primary sclerosing cholangitis | 7 (5.2) | 3 (6.4) | 4 (4.6) |  |
 Hepatitis B virus | 15 (11.1) | 4 (8.5) | 11 (12.5) |  |
 Hepatitis C virus | 51 (37.8) | 19 (40.4) | 32 (36.4) |  |
 Non-B, non-C liver cirrhosis | 13 (9.6) | 5 (10.6) | 8 (9.1) |  |
 Other | 38 (28.1) | 10 (21.3) | 28 (31.8) |  |
Comorbidity, n (%) | ||||
 Hepatocellular carcinoma | 54 (40.0) | 20 (42.6) | 34 (38.6) | 0.714 |
 Chronic kidney disease | 59 (43.7) | 23 (48.9) | 36 (40.9) | 0.467 |
Pre-operative eGFR, mL/min/1.73m2 | 66.9 (46.4–86.4) | 62.0 (43.3–87.7) | 69.8 (49.1–85.6) | 0.722 |
Post-operative eGFR, mL/min/1.73m2 | 62.8 (46.1–74.4) | 61.5 (46.2–74.1) | 63.5 (45.9–74.4) | 0.541 |
Δ eGFR (admission to discharge), mL/min/1.73m2 | 9.4 (− 10.3 to 20.8) | 9.8 (− 10.3 to 30.3) | 8.8 (− 10.7 to 18.0) | 0.567 |
MELD score | 16.0 (12.0–22.0) | 15.0 (12.0–20.0) | 17.0 (12.0–22.0) | 0.393 |
Operation time, min | 761.0 (701.0–849.0) | 798.0 (710.0–925.0) | 750.0 (695.0–820.3) | 0.036 |
Operative blood loss, g | 5550 (3550–9500) | 7000 (3140–12,670) | 4935 (3663–8735) | 0.223 |
Donor age, year | 33 (27–43) | 33 (26.0–42.0) | 33 (27.0–45.3) | 0.914 |
Left lobe graft, n (%) | 87 (64.4) | 31 (66.0) | 56 (63.6) | 0.470 |
GW/SLV, % | 40.2 (33.7–49.3) | 39.7 (33.7–44.5) | 41.4 (33.3–51.8) | 0.170 |
ABO-incompatible, n (%) | 30 (22.2) | 8 (17.0) | 22 (25.0) | 0.076 |
SMI, cm2/m2 | ||||
 Male, n (%) | 44.5 (39.0–48.8) | 44.5 (40.8–48.6) | 44.4 (37.9–49.1) | 0.803 |
 Female, n (%) | 41.0 (36.1–47.9) | 41. (37.9–49.2) | 41.1 (34.9–47.7) | 0.354 |
Initial walking, day | 9 (6–15) | 13.0 (7.0–19.0) | 8.0 (6.0–12.8) | 0.013 |
ICU length of stay, days | 5 (4–8) | 5.0 (4.0–9.0) | 5.0 (4.0–7.8) | 0.218 |
BI at admission, points | 100 (90–100) | 100 (100–100) | 100 (80–100) | 0.032 |
BI at hospital discharge, points | 100 (90–100) | 90 (70–95) | 100 (100–100) |  < 0.001 |
Hospital length of stay, days | 48.0 (37.0–67.0) | 58.0 (46.0–76.0) | 45.0 (36.0–58.8) |  < 0.001 |
Transfer to hospital, n (%) | 29 (21.6) | 18 (39.1) | 11 (12.5) | 0.001 |
Period after discharged from a hospital, months | 28.1 (27.6–28.4) | 27.8 (27.3–28.1) | 28.2 (27.8–28.4) |  < 0.001 |
Cause of death, n (%) | 13 (9.6) | 10 (21.3) | 3 (3.4) | 0.189 |
 Factors of graft side | 4 (3.0) | 4 (8.5) | 0 |  |
 Factors of recipient side | 3 (2.2) | 2 (4.3) | 1 (1.1) |  |
 Hepatocellular carcinoma recurrence | 1 (0.7) | 0 | 1 (1.1) |  |
 Other carcinoma | 3 (2.2) | 3 (6.4) | 0 |  |
 Other | 2 (1.5) | 1 (2.1) | 1 (1.1) |  |